Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated June 16, 2021, reporting matters from its 2021 annual meeting of stockholders and referencing a June 2, 2021 press release concerning initial data from its Phase 1b trial of ORIC-101 combined with nab-paclitaxel.
Financial and Operating Metrics
The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial metrics.
- Common stock outstanding at the April 19, 2021 record date: 36,695,814 shares.
- Shares represented at the annual meeting: 31,175,574, or 84.96% of shares entitled to vote.
- KPMG LLP’s appointment as independent registered public accounting firm for the year ending December 31, 2021 was ratified.
Material Changes Versus Prior Period
The filing does not report comparative financial results or identify material changes versus a prior comparable period.
Corporate Actions, Outlook, and Risks
- Richard Heyman, Ph.D., and Lori Kunkel, M.D. were elected as Class I directors to serve until the 2024 annual meeting or until their successors are elected and qualified.
- Votes for Richard Heyman: 20,152,443; withheld: 9,472,419; broker non-votes: 1,550,712.
- Votes for Lori Kunkel: 25,079,023; withheld: 4,545,839; broker non-votes: 1,550,712.
- KPMG’s appointment was approved by 31,174,833 votes for, 739 against, and 2 abstentions; there were no broker non-votes.
- The filing references initial Phase 1b clinical data for ORIC-101 in combination with nab-paclitaxel. The referenced press release and the underlying efficacy, safety, and development details are not included in the provided filing text, so the results cannot be evaluated from this information alone.
Important Facts to Verify
- Review Exhibit 99.1 for the complete Phase 1b ORIC-101 clinical data, including patient population, response measures, safety findings, and management’s interpretation.
- Confirm the company’s subsequent clinical development plans and any updated guidance regarding ORIC-101.
- Review later filings for cash runway, financing activity, operating expenses, and liquidity, none of which are disclosed in this 8-K.
- Verify the continued composition and tenure of the elected Class I directors.